Left atrial thrombosis despite dabigatran therapy

Anil Pandit, Fayaz A. Hakim, Komandoor Srivathsan, John J. Lynch

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Dabigatran is a novel anticoagulation which has been approved as an alternative to warfarin therapy for non-valvular atrial fibrillation. Use of Dabigatran for approved indications as well as off label use has dramatically increased after Federal Drug Administration (FDA) approval. Our patient had left atrial thrombosis even after being on Dabigatran for more than one month which raises question about safety and efficacy of use of dabigatran around cardioversion and ablation..

Original languageEnglish (US)
Pages (from-to)31-32
Number of pages2
JournalJournal of Atrial Fibrillation
Issue number2
StatePublished - Aug 1 2013


  • Atrial fibrillation
  • Dabigatran
  • Left atrial thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Left atrial thrombosis despite dabigatran therapy'. Together they form a unique fingerprint.

Cite this